Literature DB >> 15534270

Diffuse neurodeficits in intravascular lymphomatosis with ADAMTS13 inhibitor.

M Kawahara1, M Kanno, M Matsumoto, S Nakamura, Y Fujimura, S Ueno.   

Abstract

Inhibitory antibody to von Willebrand factor (vWF)-cleaving protease (ADAMTS13) was detected in a patient with intravascular lymphomatosis. The increased serum level of the antibody paralleled an increase in the expression of uncleaved vWF, which might cause microvascular thrombosis and platelet consumption. Malignant cell proliferations with superimposed thrombosis within the lumina throughout the entire vasculature account for diffuse neurodeficits observed in the patient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15534270     DOI: 10.1212/01.wnl.0000143065.55002.67

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

Review 1.  Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura.

Authors:  Satoru Kosugi; Masanori Matsumoto; Yasushi Ohtani; Hironori Take; Hiromichi Ishizashi; Yoshihiro Fujimura; Jun Kuyama
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  Chemotherapy-resistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab.

Authors:  Masatoshi Kanno; Shinobu Nakamura; Makoto Kawahara; Satoshi Ueno; Hirokazu Nakamine; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  Int J Hematol       Date:  2008-08-19       Impact factor: 2.490

Review 3.  Kidney injury and disease in patients with haematological malignancies.

Authors:  Frank Bridoux; Paul Cockwell; Ilya Glezerman; Victoria Gutgarts; Jonathan J Hogan; Kenar D Jhaveri; Florent Joly; Samih H Nasr; Deirdre Sawinski; Nelson Leung
Journal:  Nat Rev Nephrol       Date:  2021-03-30       Impact factor: 28.314

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.